Celltrion Files Amendment to US Phase 3 Clinical Trial Plan for CT-P51 Keytruda Biosimilar
Celltrion submitted an amendment to the US FDA on July 6 2026 for its global Phase 3 clinical trial plan for CT-P51 a Keytruda biosimilar.
The amendment covers a double-blind randomized active-controlled trial comparing efficacy and safety of CT-P51 versus Keytruda in 220 treatment-naive patients with metastatic non-squamous non-small cell lung cancer with a treatment period of 2 years.
Statistically the probability of final regulatory approval for a clinical-stage drug is approximately 10% so investors should consider the inherent risks of biosimilar development.
[AI Summary]This filing is an administrative milestone with no immediate capital or financial impact. However given the low probability of success typical in drug development continuous monitoring of clinical outcomes and regulatory progress is essential for shareholder value assessment.
KOSPI Filing Information
Major Management Matters Related to Investment Decision (CTP51 (Keytruda Biosimilar) US Phase 3 Clinical Trial Plan Change Application)